MCID: GLM045
MIFTS: 51

Glioma

Categories: Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Glioma

MalaCards integrated aliases for Glioma:

Name: Glioma 19 75 28 53 5 16 71

Classifications:



External Ids:

UMLS 71 C0017638

Summaries for Glioma

GARD: 19 Glioma refers to a type of brain tumor that develops from the glial cells, which are specialized cells that surround and support neurons (nerve cells) in the brain. It is generally classified based on which type of glial cell is involved in the tumor: Astocytoma - tumors that develop from star-shaped glial cells called astrocytes Ependymomas - tumors that arise from ependymal cells that line the ventricles of the brain and the center of the spinal cord OligodendroGliomas - tumors that affect the oligodendrocytes The symptoms of Glioma vary by type but may include headaches; nausea and vomiting; confusion; personality changes; trouble with balance; vision problems; speech difficulties; and/or seizures. The exact underlying cause is unknown. In most cases, the tumor occurs sporadically in people with no family history of the condition.

MalaCards based summary: Glioma is related to high grade glioma and brain cancer. An important gene associated with Glioma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Cell differentiation - expanded index and miRNAs involved in DNA damage response. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells.

Wikipedia: 75 A glioma is a type of tumor that starts in the glial cells of the brain or the spine. Gliomas comprise... more...

Related Diseases for Glioma

Diseases related to Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1381)
# Related Disease Score Top Affiliating Genes
1 high grade glioma 33.1 PVT1 NEAT1 MIR221 MIR21 MIR17 MEG3
2 brain cancer 32.4 NTRK3 MIR34A MIR296 MIR222 MIR221 MIR21
3 glioblastoma 32.3 MIR34A MIR296 MIR222 MIR221 MIR21 MIR181A2
4 malignant astrocytoma 32.2 MIR34A MIR296 MIR222 MIR221 MIR21 MIR17
5 neuroblastoma 31.7 NTRK3 MIR34A MIR221 MIR21 MIR184 MIR17
6 central nervous system cancer 31.6 MIR34A MIR296 MIR222 MIR221 MIR21 MIR17
7 visual epilepsy 31.4 NEAT1 MALAT1
8 meningioma, familial 31.3 MIR34A MIR15B MEG3 H19
9 medulloblastoma 31.3 NTRK3 MIR34A MIR221 MIR17 H19 FOXO1
10 burkitt lymphoma 31.1 PVT1 NEAT1 MIR21 FOXO1
11 osteogenic sarcoma 31.0 PVT1 NEAT1 MEG3 MALAT1 H19 GAS5
12 leukemia, acute lymphoblastic 30.9 MIR222 MIR221 MIR21 MIR17 CDKN2B-AS1
13 lung cancer susceptibility 3 30.8 MIR296 MIR21 MIR17 MEG3 MALAT1 H19
14 melanoma 30.8 PVT1 MIR34A MIR222 MIR221 MIR21 MIR184
15 retinitis pigmentosa 11 30.7 PVT1 NEAT1 MIR296 GAS5 CDKN2B-AS1
16 thyroid carcinoma 30.7 PVT1 NEAT1 MALAT1 H19 GAS5 CDKN2B-AS1
17 cholangiocarcinoma 30.7 NEAT1 MIR21 MALAT1 H19
18 central nervous system disease 30.6 MIR34A MIR222 MIR221 MIR21 MIR17 MIR15B
19 peripheral nervous system disease 30.6 NTRK3 MIR34A MIR21 MIR17 FOXO1
20 cerebrovascular disease 30.6 MIR221 MIR21 MIR17 MEG3
21 parkinson disease, late-onset 30.6 NEAT1 MIR21 MIR15B MALAT1 H19 FOXO1
22 alzheimer disease, familial, 1 30.6 NTRK3 MIR34A MIR21 MIR17 MIR15B CDKN2B-AS1
23 bladder cancer 30.5 PVT1 MIR222 MIR221 MIR21 MIR17 MEG3
24 lung cancer 30.5 PVT1 NEAT1 MIR34A MIR296 MIR222 MIR221
25 leukemia, acute myeloid 30.5 MIR34A MIR296 MIR222 MIR221 MIR21 MIR184
26 diffuse large b-cell lymphoma 30.5 MIR222 MIR221 MIR21 MIR17
27 ovarian cancer 30.5 PVT1 NEAT1 MIR34A MIR296 MIR222 MIR221
28 acute promyelocytic leukemia 30.5 PVT1 NEAT1 MIR221 MIR17 MIR15B MIR146B
29 esophageal cancer 30.5 PVT1 MIR34A MIR296 MIR222 MIR221 MIR21
30 myelodysplastic syndrome 30.5 MIR34A MIR222 MIR221 MIR17 MEG3
31 esophagus squamous cell carcinoma 30.4 PVT1 MIR296 MEG3 MALAT1 GAS5
32 kidney cancer 30.4 PVT1 MIR21 MIR17 MEG3 MALAT1 H19
33 prostate cancer 30.4 PVT1 NEAT1 MIR34A MIR296 MIR222 MIR221
34 breast cancer 30.4 PVT1 NTRK3 NEAT1 MIR34A MIR222 MIR221
35 hematologic cancer 30.4 PVT1 MIR34A MIR222 MIR221 MIR21 MIR17
36 hepatocellular carcinoma 30.4 PVT1 NEAT1 MIR34A MIR296 MIR222 MIR221
37 gastric cancer 30.4 PVT1 NEAT1 MIR34A MIR222 MIR221 MIR21
38 immune deficiency disease 30.4 NEAT1 MIR34A MIR221 MIR21 MIR17 MIR146B
39 ovarian epithelial cancer 30.3 MEG3 MALAT1 H19
40 pancreatic cancer 30.3 PVT1 NEAT1 MIR34A MIR222 MIR221 MIR21
41 laryngeal squamous cell carcinoma 30.3 NEAT1 MIR21 MALAT1 H19 CDKN2B-AS1
42 renal cell carcinoma, nonpapillary 30.3 PVT1 MIR34A MIR296 MIR222 MIR221 MIR21
43 body mass index quantitative trait locus 11 30.2 MIR34A MIR222 MIR221 MIR21 MIR17 MIR146B
44 bone disease 30.2 MIR34A MIR222 MIR221 MIR21 MIR17
45 diabetes mellitus 30.2 PVT1 MIR34A MIR222 MIR21 MIR181A2 MIR17
46 leukemia, chronic lymphocytic 30.2 NEAT1 MIR34A MIR221 MIR21 MIR181A2 MIR17
47 head and neck cancer 30.2 MIR34A MIR296 MIR222 MIR221 MIR21 MIR17
48 pancreatic ductal adenocarcinoma 30.2 PVT1 MIR34A MIR222 MIR221 MIR21 MIR17
49 squamous cell carcinoma, head and neck 30.1 MIR222 MIR221 MIR21 MIR17 MIR146B H19
50 lymphoma, non-hodgkin, familial 30.1 MIR34A MIR222 MIR21 MIR17 MIR15B MIR146B

Graphical network of the top 20 diseases related to Glioma:



Diseases related to Glioma

Symptoms & Phenotypes for Glioma

Drugs & Therapeutics for Glioma

Drugs for Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 462)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
3
Lactitol Approved, Investigational Phase 4 585-86-4 157355
4
Temozolomide Approved, Investigational Phase 4 85622-93-1 5394
5 Alkylating Agents Phase 4
6 Antineoplastic Agents, Alkylating Phase 4
7
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
8
Ifosfamide Approved Phase 3 3778-73-2 3690
9
Dextroamphetamine Approved, Illicit, Investigational Phase 3 51-64-9, 300-62-9 5826 3007
10
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605 16129706
11
Ethanol Approved Phase 2, Phase 3 64-17-5 702
12
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
13
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
14
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
15
Trioxsalen Approved Phase 3 3902-71-4 5585
16
Vorinostat Approved, Investigational Phase 2, Phase 3 149647-78-9 5311
17
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
18
Vinblastine Approved Phase 3 865-21-4 241903 13342
19
Carbidopa Approved Phase 3 28860-95-9 34359 38101
20
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
21
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
22
Ascorbic acid Approved, Nutraceutical Phase 3 50-81-7 54676860 54670067 5785
23
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
24
Palifosfamide Investigational Phase 3 31645-39-3 100427
25
Diethyl ether Experimental Phase 3 60-29-7 3283
26
Dihematoporphyrin ether Investigational Phase 3 97067-70-4
27
Nimotuzumab Investigational Phase 3 780758-10-3
28
Dianhydrogalactitol Investigational Phase 3 23261-20-3
29 Protective Agents Phase 3
30 Antioxidants Phase 3
31 Interferon-alpha Phase 3
32 Vitamins Phase 3
33 Dopamine Uptake Inhibitors Phase 3
34
Edotreotide Phase 2, Phase 3 23724894
35 Trace Elements Phase 2, Phase 3
36 Micronutrients Phase 2, Phase 3
37 Anesthetics Phase 3
38 Central Nervous System Stimulants Phase 3
39 Anesthetics, General Phase 3
40 Copper Supplement Phase 2, Phase 3
41 Hematoporphyrin Derivative Phase 3
42 Anesthetics, Inhalation Phase 3
43 Hematoporphyrins Phase 3
44 N-Methylaspartate Phase 3
45 Immunoglobulin G Phase 2, Phase 3
46 Endothelial Growth Factors Phase 2, Phase 3
47 Fluorophosphate Phase 3
48
D-Leucine Experimental, Investigational, Nutraceutical Phase 3 328-38-1, 61-90-5 439524 6106
49
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
50
Arsenic trioxide Approved, Investigational Phase 1, Phase 2 1327-53-3 518740

Interventional clinical trials:

(show top 50) (show all 1332)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
3 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
4 A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma Recruiting NCT04650204 Phase 4 Anticonvulsant Agent;Perampanel
5 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
6 Pilot Study Evaluating the Optimization of the ORBEYE Blue Light Filter During Fluorescence-Guided Resection of Gliomas Recruiting NCT04937244 Phase 4
7 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
8 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
9 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
10 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Unknown status NCT03633552 Phase 3 Temozolomide
11 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
12 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
13 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Unknown status NCT02455245 Phase 3 Carboplatin;Vincristine
14 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
15 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
16 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
17 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
18 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
19 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
20 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
21 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
22 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
23 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma Completed NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
24 3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial Completed NCT01479686 Phase 3
25 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
26 DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial Completed NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
27 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Completed NCT03042416 Phase 3 18F-DOPA
28 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Completed NCT02892708 Phase 3
29 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
30 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
31 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
32 A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Recruiting NCT04576117 Phase 3 Selumetinib Sulfate;Vinblastine Sulfate
33 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
34 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
35 A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Recruiting NCT03871257 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
36 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
37 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication Recruiting NCT05476939 Phase 3 Everolimus;ONC201
38 A Multicenter, Prospective, Open and Single Arm Clinical Study of Nimotuzumab Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children Recruiting NCT04532229 Phase 3 Nimotuzumab+CRT(concurrent IMRT and TMZ)
39 ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Recruiting NCT05580562 Phase 3 ONC201;ONC201 + Placebo
40 Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial Recruiting NCT05331521 Phase 3 CETEG;PCV
41 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
42 Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study Recruiting NCT03534050 Phase 2, Phase 3
43 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy Recruiting NCT05479136 Phase 3 PET imaging with 18F fluciclovine
44 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Basket Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis Recruiting NCT05503264 Phase 3 Satralizumab
45 Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery Recruiting NCT04316039 Phase 2, Phase 3 Temozolomide
46 A Phase III Randomized Trial of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (Avastin) With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed Glioblastoma (GBM) Recruiting NCT05271240 Phase 3 Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation;Temozolomide and Radiation Alone
47 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
48 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Active, not recruiting NCT04164901 Phase 3 Vorasidenib;Matching Placebo
49 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
50 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Active, not recruiting NCT00045968 Phase 3 Dendritic cell immunotherapy

Search NIH Clinical Center for Glioma

Genetic Tests for Glioma

Genetic tests related to Glioma:

# Genetic test Affiliating Genes
1 Glioma 28

Anatomical Context for Glioma

Organs/tissues related to Glioma:

MalaCards : Brain, Spinal Cord, T Cells, Bone Marrow, Endothelial, Cortex, Myeloid

Publications for Glioma

Articles related to Glioma:

(show top 50) (show all 31409)
# Title Authors PMID Year
1
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. 53 62 46
19773441 2009
2
Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. 53 62 46
19424584 2009
3
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. 53 62 46
18591254 2008
4
Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. 62 46
19775293 2010
5
MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. 62 46
19536818 2009
6
microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. 62 46
19265686 2009
7
MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. 62 46
19135980 2009
8
hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. 62 46
18710654 2008
9
MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. 62 46
17908999 2007
10
JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration. 53 62
20514406 2010
11
AKT2 expression is associated with glioma malignant progression and required for cell survival and invasion. 53 62
20514445 2010
12
Intussusceptive microvascular growth in human glioma. 53 62
19882213 2010
13
A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. 53 62
20375153 2010
14
Glioma cell populations grouped by different cell type markers drive brain tumor growth. 53 62
20460538 2010
15
The carboxy-terminal tail of connexin43 gap junction protein is sufficient to mediate cytoskeleton changes in human glioma cells. 53 62
20512920 2010
16
Combination therapy with Gamma Knife radiosurgery and antisense EGFR for malignant glioma in vitro and orthotopic xenografts. 53 62
20428813 2010
17
Gene expression profiling predicts response to temozolomide in malignant gliomas. 53 62
20428759 2010
18
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. 53 62
20382206 2010
19
FasL gene knock-down therapy enhances the antiglioma immune response. 53 62
20406899 2010
20
Nodal promotes growth and invasion in human gliomas. 53 62
20383200 2010
21
Induction of apoptosis in glioma cells requires cell-to-cell contact with human umbilical cord blood stem cells. 53 62
20372790 2010
22
Imaging of human glioma cells by means of a Syndecan-4 directed DOTA-conjugate. 53 62
19777324 2010
23
TRPV2 channel negatively controls glioma cell proliferation and resistance to Fas-induced apoptosis in ERK-dependent manner. 53 62
20093382 2010
24
Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. 53 62
20404698 2010
25
Genetic variants in inflammation pathway genes and asthma in glioma susceptibility. 53 62
20406895 2010
26
Human neural stem cells transduced with IFN-beta and cytosine deaminase genes intensify bystander effect in experimental glioma. 53 62
19893595 2010
27
Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. 53 62
20411591 2010
28
RECK-mediated inhibition of glioma migration and invasion. 53 62
20127710 2010
29
Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo. 53 62
20406896 2010
30
Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. 53 62
19856144 2010
31
Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner. 53 62
20442305 2010
32
Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. 53 62
19810093 2010
33
Clinical and biological significance of forkhead class box O 3a expression in glioma: mediation of glioma malignancy by transcriptional regulation of p27kip1. 53 62
19911116 2010
34
Astrocyte elevated gene-1 upregulates matrix metalloproteinase-9 and induces human glioma invasion. 53 62
20388776 2010
35
Akt signaling pathway: a target for radiosensitizing human malignant glioma. 53 62
20406894 2010
36
CD40 is a regulator for vascular endothelial growth factor in the tumor microenvironment of glioma. 53 62
20303602 2010
37
Protective effect of autophagy in laser-induced glioma cell death in vitro. 53 62
20432283 2010
38
Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. 53 62
20188714 2010
39
Cooperative expression of junctional adhesion molecule-C and -B supports growth and invasion of glioma. 53 62
19795504 2010
40
Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. 53 62
20338480 2010
41
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. 53 62
20308316 2010
42
Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. 53 62
20140015 2010
43
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. 53 62
20388803 2010
44
Molecular interaction and functional regulation of ClC-3 by Ca2+/calmodulin-dependent protein kinase II (CaMKII) in human malignant glioma. 53 62
20139089 2010
45
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. 53 62
20436671 2010
46
Target gene therapy of glioma: overexpression of BAX gene under the control of both tissue-specific promoter and hypoxia-inducible element. 53 62
20383466 2010
47
Erratum to: Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells. 53 62
20119650 2010
48
Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. 53 62
20233866 2010
49
Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. 53 62
19626585 2010
50
Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. 53 62
20410111 2010

Variations for Glioma

ClinVar genetic disease variations for Glioma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NTRK3 t(12;15)(p13;q25) VAR Pathogenic
1195985 GRCh37:
GRCh38:
2 overlap with 188 genes COMPLEX Likely Pathogenic
617751 GRCh37: 9:23524426-87359888
GRCh38:
3 VPS35, FGFR2 t(10;16)(q26;q11) TRANS Likely Pathogenic
930214 GRCh37: 10:123241693-123243211
GRCh38:
4 RAF1 NM_002880.4(RAF1):c.673C>T (p.Pro225Ser) SNV Benign
1195988 GRCh37: 3:12647707-12647707
GRCh38: 3:12606208-12606208

Copy number variations for Glioma from CNVD:

6 (show top 50) (show all 1065)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13321 2 208809197 208828051 Copy number IDH1 Glioma
2 14132 1 10403401 10408000 Deletion Glioma
3 14198 1 105227801 105232100 Deletion Glioma
4 15004 1 111800000 116100000 Deletion Glioma
5 15199 1 113411001 113417300 Deletion Glioma
6 15250 1 113839501 113849000 Deletion Glioma
7 15641 1 117679901 117685200 Deletion Glioma
8 15695 1 118394101 118397900 Deletion Glioma
9 19119 1 148648801 148652600 Deletion Glioma
10 19806 1 151480801 151485400 Deletion Glioma
11 20843 1 154791301 154797500 Deletion IQGAP3 Glioma
12 21174 1 157132201 157138600 Deletion Glioma
13 21291 1 157913501 157918300 Deletion Glioma
14 21685 1 160317401 160321200 Deletion Glioma
15 23692 1 173061201 173070300 Deletion Glioma
16 24042 1 174742901 174746800 Deletion Glioma
17 24302 1 178448601 178452400 Deletion Glioma
18 25156 1 185029601 185033600 Deletion Glioma
19 25220 1 185729601 185734900 Deletion Glioma
20 25241 1 185980701 185991100 Deletion Glioma
21 25290 1 186804101 186808700 Deletion Glioma
22 25655 1 192615401 192619700 Deletion Glioma
23 26024 1 195765301 195771800 Deletion Glioma
24 26054 1 196268601 196275300 Deletion Glioma
25 26178 1 197703301 197708700 Deletion Glioma
26 26883 1 20368201 20372100 Deletion PLA2G2C Glioma
27 26979 1 204445801 204451500 Deletion Glioma
28 27209 1 205357001 205361800 Deletion Glioma
29 27636 1 210535701 210541200 Deletion Glioma
30 27909 1 215522601 215526900 Deletion Glioma
31 27938 1 216247201 216257200 Deletion Glioma
32 27948 1 216310301 216315100 Deletion Glioma
33 28054 1 217987801 217992100 Deletion Glioma
34 28169 1 219443901 219451100 Deletion Glioma
35 28238 1 220438701 220448900 Deletion Glioma
36 28860 1 226089101 226092600 Deletion Glioma
37 29433 1 232027401 232031900 Deletion Glioma
38 29707 1 234613701 234620000 Deletion Glioma
39 29744 1 234984301 234988400 Deletion ACTN2 Glioma
40 29950 1 238457901 238463400 Deletion Glioma
41 29974 1 238682401 238685500 Deletion Glioma
42 30033 1 239425501 239429300 Deletion Glioma
43 30273 1 241490101 241494000 Deletion Glioma
44 30527 1 244220301 244224400 Deletion Glioma
45 30564 1 244503701 244507900 Deletion Glioma
46 30805 1 246116501 246126100 Deletion OR2W3 Glioma
47 31058 1 25029301 25036000 Deletion Glioma
48 31536 1 28129101 28135200 Deletion SMPDL3B Glioma
49 31728 1 30200000 32400000 Deletion Glioma
50 33111 1 42513801 42517800 Deletion FOXJ3 Glioma

Expression for Glioma

Search GEO for disease gene expression data for Glioma.

Pathways for Glioma

Pathways related to Glioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.25 MIR222 MIR221 MIR181A2 MIR17 MIR146B
2 10.85 MIR222 MIR221 MIR21 MIR17 MIR15B

GO Terms for Glioma

Cellular components related to Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.72 NEAT1 MIR296 MIR222 MIR221 MIR21 MIR184
2 extracellular vesicle GO:1903561 9.43 MIR34A MIR222 MIR221 MIR21 MIR17 MIR15B

Biological processes related to Glioma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.14 PVT1 NTRK3 MIR34A MIR21 MIR17 CDKN2B-AS1
2 positive regulation of cell migration GO:0030335 10.02 NTRK3 MIR296 MIR21 MIR181A2 CDKN2B-AS1
3 negative regulation of gene expression GO:0010629 9.99 CDKN2B-AS1 MIR17 MIR181A2 MIR21 MIR34A
4 negative regulation of inflammatory response GO:0050728 9.87 MIR222 MIR221 MIR181A2 MIR15B
5 positive regulation of protein kinase B signaling GO:0051897 9.86 MIR222 MIR221 MIR21 H19
6 negative regulation of angiogenesis GO:0016525 9.83 MIR34A MIR222 MIR21 MIR15B
7 negative regulation of miRNA-mediated gene silencing GO:0060965 9.79 PVT1 NEAT1
8 positive regulation of epithelial to mesenchymal transition GO:0010718 9.78 MIR222 MIR221 MIR21
9 miRNA-mediated gene silencing GO:0035195 9.7 NEAT1 MIR34A MIR296 MIR222 MIR221 MIR21
10 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.67 H19 MIR17 MIR21
11 positive regulation of axon regeneration GO:0048680 9.64 MIR222 MIR221
12 negative regulation of cell adhesion molecule production GO:0060354 9.63 MIR222 MIR221
13 negative regulation by host of viral genome replication GO:0044828 9.63 MIR222 MIR221
14 positive regulation of connective tissue replacement GO:1905205 9.62 MIR34A MIR15B
15 negative regulation of vascular associated smooth muscle cell differentiation GO:1905064 9.62 MIR221 MIR15B
16 negative regulation of sprouting angiogenesis GO:1903671 9.61 MIR34A MIR221 MIR17
17 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.58 MIR21 MIR17
18 positive regulation of metalloendopeptidase activity GO:1904685 9.58 MIR21 MIR17
19 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.56 MIR222 MIR221 MIR21 MIR17
20 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.54 MIR222 MIR221
21 negative regulation of vascular endothelial growth factor production GO:1904046 9.54 MIR34A MIR17 MIR15B
22 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.51 MIR222 MIR221
23 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.48 MIR222 MIR221
24 positive regulation of Schwann cell migration GO:1900149 9.46 MIR222 MIR221
25 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.43 MIR15B MIR17 MIR181A2 MIR21 MIR221 MIR222
26 negative regulation of superoxide dismutase activity GO:1901670 9.4 MIR21 H19
27 negative regulation of interleukin-21 production GO:0032705 9.33 MIR222 MIR221 MIR21
28 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.32 MIR222 MIR221

Molecular functions related to Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA binding GO:0035198 9.46 PVT1 NEAT1 GAS5
2 mRNA 3'-UTR binding GO:0003730 9.43 MIR34A MIR296 MIR21 MIR181A2 MIR17 MIR15B
3 mRNA base-pairing translational repressor activity GO:1903231 9.28 MIR34A MIR296 MIR222 MIR221 MIR21 MIR181A2

Sources for Glioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....